Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

Bolt’s innate immune-activating take on ADCs could bring durable antitumor activity to more patients

July 2, 2020 1:51 AM UTC

Bolt’s $93.5 million series C round will enable the Stanford spinout to clinically test whether its myeloid-activating antibody conjugate can provide durable treatment to a broad swath of HER2-positive solid tumor patients.

Led by Sofinnova Investments, the round also included new investors RA Capital Management, Surveyor Capital, Rock Springs Capital, Samsara BioCapital and Pfizer Ventures, along with existing investors including Novo Holdings, Vivo Capital, Pivotal bioVenture Partners. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article